NVDA
NVIDIA
-- 142.620 TSLA
Tesla
-- 406.580 PLTR
Palantir
-- 78.980 AAPL
Apple
-- 222.780 MSTR
MicroStrategy
-- 353.670 
NEWS TODAY
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Wednesday, 8th January at 7:00 am
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile
Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points
100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks
Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels
Data supports commencement of CSU registrational program expected to commence second half of 2025
Wednesday, 8th January at 7:00 am
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile
Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points
100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks
Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels
Data supports commencement of CSU registrational program expected to commence second half of 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
7061
Followers
46
Following
76K
Visitors
Follow
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day